| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/16/2013 | CN102872066A Ivermectin and application of derivative thereof |
| 01/16/2013 | CN102872061A Composition of creatine phosphate and arginine |
| 01/16/2013 | CN102872048A Application of gypensapogenin B to ischemic brain injury treatment drugs |
| 01/16/2013 | CN102872044A Application of Gypensapogenin A in medicaments for vasodilator |
| 01/16/2013 | CN102872031A Application of Gypensapogenin B in medicaments for treating or preventing chronic heart failure |
| 01/16/2013 | CN102872020A Inhibitor of pai-1 production |
| 01/16/2013 | CN102872012A Compound capable of inhibiting protein kinase and application thereof |
| 01/16/2013 | CN102872002A Hydroxysafflor yellow A oil solution and preparation method and application thereof |
| 01/16/2013 | CN102871998A Application of nafamostat mesilate in preparing drugs for preventing and curing ischemic cerebral apoplexy |
| 01/16/2013 | CN102871990A Pharmaceutical application of resveratrol |
| 01/16/2013 | CN102871981A Tablet medicine compound containing levetiracetam |
| 01/16/2013 | CN102871970A Puerarin oral adhesion microballoon spheres and preparation method thereof |
| 01/16/2013 | CN102871961A Injection containing tirofiban |
| 01/16/2013 | CN102871950A 一种熊果酸固体分散体及其制备方法 One kind of ursolic acid solid dispersion and its preparation method |
| 01/16/2013 | CN102871071A Ginger powder and processing method thereof |
| 01/16/2013 | CN102870928A Health-care and blood pressure-lowering tea |
| 01/16/2013 | CN102397245B Nicardipine hydrochloride glucose injection |
| 01/16/2013 | CN102240391B Traditional Chinese medicine solution for health promotion |
| 01/16/2013 | CN102225095B Effective fraction of plantain seeds as well as preparation method and application thereof |
| 01/16/2013 | CN102180928B 3-beta,5-alpha,6-beta-trihydroxy steroid compounds, and synthesis method and application thereof |
| 01/16/2013 | CN102144987B Metoprolol oral pulsatile tablet and preparation method and application of metoprolol oral pulsatile tablet |
| 01/16/2013 | CN101869633B Enteric-coated medicament combination containing epigallocatechin gallate |
| 01/16/2013 | CN101791320B Application of nano carbon particles in preparing external medicament for curing haemorrhoids and external medicament |
| 01/16/2013 | CN101306191B Use of TLR2 ligand PGN in treating metabolism syndrome |
| 01/15/2013 | US8354448 Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes |
| 01/15/2013 | US8354416 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors |
| 01/15/2013 | US8354407 2-anilino-4-(heterocyclic)amino-pyrimidines |
| 01/15/2013 | US8354402 Polyarylcarboxamides useful as lipid lowering agents |
| 01/15/2013 | US8354394 Diuretics |
| 01/15/2013 | CA2753345C 1,4-benzothiazepine-1-oxide derivative and pharmaceutical composition utilizing the same |
| 01/15/2013 | CA2430133C Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
| 01/15/2013 | CA2427774C Inhibitors of thromboxane formation and action |
| 01/15/2013 | CA2406725C Edg8 receptor, its preparation and use |
| 01/10/2013 | WO2013006841A1 Stimulation of arterial collateral growth and lymphogenesis |
| 01/10/2013 | WO2013006364A1 Establishment of patient - or person - specific cardiac myocyte cell lines from human induced pluripotent stem cells (ipscs) |
| 01/10/2013 | WO2013005839A1 Phosphorylated peptide, hard tissue and/or ectopic calcification inhibitor, antibody, and hard tissue and/or ectopic calcification promoter |
| 01/10/2013 | WO2013005755A1 Methylpiperidine derivative |
| 01/10/2013 | WO2013005698A1 Biological inorganic compound complex having reduced oxygen and high reducing ability |
| 01/10/2013 | WO2013005017A1 Cannabinoids for use in the treatment of neurodegenerative diseases or disorders |
| 01/10/2013 | WO2013004984A1 Tricyclic compounds for use as kinase inhibitors |
| 01/10/2013 | WO2013004831A1 Dronedarone for the prevention of atrial fibrillation |
| 01/10/2013 | WO2013004830A1 Pharmaceutical composition and solid galenic form having a high dronedarone content, and method for preparing same |
| 01/10/2013 | WO2013004828A1 Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| 01/10/2013 | WO2013004827A1 Carboxylic acid derivatives having an oxazolo[5,4-d]pyridine ring |
| 01/10/2013 | WO2013004177A1 Composition of active ingredient of traditional chinese medicine and use thereof |
| 01/10/2013 | WO2012149167A9 Method and device for treatment of hypertension and other maladies |
| 01/10/2013 | WO2012141487A3 Cycloalkenyl aryl derivatives for cetp inhibitor |
| 01/10/2013 | US20130012603 Methods for assessing the risk of cardiovascular disease |
| 01/10/2013 | US20130012592 Agomelatine hydrobromide hydrate and preparation thereof |
| 01/10/2013 | US20130012583 Vinyl substituted fatty acids |
| 01/10/2013 | US20130012576 Composition for Lowering Blood Lipid and Elevating High-density Lipoprotein and Method for Manufacturing the Same |
| 01/10/2013 | US20130012571 Organic Compositions to Treat Beta-ENaC-Related Diseases |
| 01/10/2013 | US20130012568 Kits for Detecting Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods |
| 01/10/2013 | US20130012548 Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds |
| 01/10/2013 | US20130012545 Amido-Thiophene Compounds and Their Use |
| 01/10/2013 | US20130012538 Compositions and methods for the treatment of metabolic disorders |
| 01/10/2013 | US20130012532 Cyclopropanecarboxylic acid derivative |
| 01/10/2013 | US20130012529 Heterobicyclic carboxamides as inhibitors for kinases |
| 01/10/2013 | US20130012521 Apoptosis signal-regulating kinase inhibitors |
| 01/10/2013 | US20130012517 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors |
| 01/10/2013 | US20130012515 Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors |
| 01/10/2013 | US20130012511 Soluble guanylate cyclase activators |
| 01/10/2013 | US20130012510 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 |
| 01/10/2013 | US20130012505 Benzonaphthyridinamines as autotaxin inhibitors |
| 01/10/2013 | US20130012499 Trpv4 antagonists |
| 01/10/2013 | US20130012498 5ht2c receptor modulators |
| 01/10/2013 | US20130012495 5ht2c receptor modulators |
| 01/10/2013 | US20130012494 Cyclopropyl-fused-1,3-thiazepines as bace1 and/or bace2 inhibitors |
| 01/10/2013 | US20130012492 Fused heterocyclic compounds as ion channel modulators |
| 01/10/2013 | US20130012486 Combination steroid and glucocorticoid receptor antagonist therapy |
| 01/10/2013 | US20130012485 Organic compounds |
| 01/10/2013 | US20130012479 Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012459 Composition for inhibiting the onset of arteriosclerosis and inhibition method |
| 01/10/2013 | US20130012458 7-hydroxy chromones as potent antioxidants |
| 01/10/2013 | US20130012444 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012438 Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| 01/10/2013 | US20130012434 Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use |
| 01/10/2013 | US20130012433 Method for reducing cardiovascular morbidity and mortality in prediaetic patients and patients with type 2 diabetes |
| 01/10/2013 | US20130012432 Peptides for Treatment of Obesity |
| 01/10/2013 | US20130012427 Polypeptides |
| 01/10/2013 | US20130011852 Compounds that interact with kinases |
| 01/10/2013 | US20130011487 Fluorinated block co-polymers |
| 01/10/2013 | US20130011482 Dual component medicament delivery system |
| 01/10/2013 | US20130011472 Stable pharmaceutical composition and methods of using same |
| 01/10/2013 | US20130011471 Stable pharmaceutical composition and methods of using same |
| 01/10/2013 | US20130011445 Polymer-agent conjugates, particles, compositions, and related methods of use |
| 01/10/2013 | US20130011409 Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1 |
| 01/10/2013 | US20130011405 Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| 01/10/2013 | US20130011398 Serpin Fusion Polypeptides and Methods of Use Thereof |
| 01/10/2013 | US20130011397 Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain |
| 01/10/2013 | US20130011396 Treatment protocol |
| 01/10/2013 | US20130011390 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 01/10/2013 | US20130011373 Side population cells in cardiac repair |
| 01/10/2013 | US20130011371 ESTABLISHMENT OF PATIENT- OR PERSON- SPECIFIC CARDIAC MYOCYTE CELL LINES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS (iPSCs) |
| 01/10/2013 | US20130011367 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| 01/10/2013 | US20130011361 Pyrazole derivatives which modulate stearoyl-coa desaturase |
| 01/10/2013 | US20130011337 Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases |
| 01/10/2013 | US20130011335 Materials and Methods Related to Sodium/Potassium Adenosine Triphosphate and SRC |
| 01/10/2013 | CA2841229A1 Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| 01/10/2013 | CA2841226A1 Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring |